Recent News AGN.c AGNPF is continuing to be a leader in the discovery of new therapeutic uses for drugs that are off patent and have a well-known safety history, but have never been marketed in the U.S. or Europe.
Highlights of recent news
- Completed the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (DMT) for stroke and have been approved to move forward
- Received a Notice of Allowance from the US Patent and Trademark Office for patent application for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast)
Considering the stroke treatment market is est. to reach value of $15B by 2027 and more than 1 in 7 (15% of US adults or 37 million people) are estimated to have chronic kidney disease AGN continues to be a leader in large market opportunities.
https://www.algernonpharmaceuticals.com/news-media/news-releases